- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | Lilly's oral GLP-1 drug delivers Ozempic-like efficacy in phase 3 diabetes trial | ||
| 16.04. | Novartis terminates phase 2 osteoarthritis trial testing ADAMTS-5 inhibitor | ||
| 16.04. | HHS abruptly terminates funding for Atlanta biotech's trio of next-gen vaccine studies | ||
| 16.04. | Glycomine grabs $115M series C to fund phase 2 journey for rare genetic disorder drug | ||
| 16.04. | Investor pressures struggling Essa to liquidate, give cash to shareholders | ||
| 16.04. | Telix points to 'promising' 13-month survival rate in phase 2 brain cancer radiopharma study | ||
| 15.04. | Merck inks $493M biobucks deal to use Cyprumed's tech to create oral peptides | ||
| 15.04. | Spruce smartens up pipeline with deal for BioMarin asset, plans 2026 approval filing | ||
| 15.04. | Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives | ||
| 15.04. | NAYA Biosciences spins off cancer drug business 6 months after INVO merger | ||
| 15.04. | Sanofi's high hopes for $1.1B Kymab anti-inflammatory drug dented after phase 2 asthma failure | ||
| 15.04. | Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack | ||
| 14.04. | 'One of the lucky few': Bicara's CEO on operating in today's market, while hoping for a different one | ||
| 14.04. | Ironwood rethinks options after FDA demands another phase 3 trial for GI drug | ||
| 14.04. | Third Harmonic's song to end as biotech looks to liquidate, sell off urticaria drug | ||
| 14.04. | Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan | ||
| 14.04. | Verve Therapeutics' 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision | ||
| 11.04. | Market volatility compounds 'already challenging' year for biotech IPOs | ||
| 11.04. | Time runs out for Kronos' headquarters amid wider cost-cutting exercise | ||
| 10.04. | Biotech leaders urge Senate to restore FDA's key functions, cite funding concerns for small companies | ||
| 10.04. | Pfizer shakes up R&D presence in San Diego with $255M site sale, 56 layoffs | ||
| 10.04. | Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout | ||
| 10.04. | Keros considers a sale, strengthens defense against potential activist investors | ||
| 10.04. | Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops | ||
| 10.04. | Tempest, weathering stormy capital markets, hunts for partners for liver cancer drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
